• day ::

This product was successfully added to cart!

View Shopping Cart

HiScript II Reverse Transcriptase R201

HiScript II Reverse Transcriptase R201

SKU: #001 - In Stock
  • R201-01: Sales specifications: 2000 U
  • R201-02: Sales specifications: 10000 U
  • USD$0.00

    Please note that pricing may vary due to different countries and regions

    Request Contact

    Click and submit your question and we will get back to you within one business day

    Product Detail

    Application Notes

    Customer Reviews

    Product Tags

    Product Introduction

    HiScript II Reverse Transcriptase is a new generation reverse transcriptase optimized from the M-MLV (RNase H-) Reverse Transcriptase. Compared with the last generation reverse transcriptase, the thermo-stability of this product is significantly improved. The half-life of HiScript II Reverse Transcriptase at 50℃ is >240 min. At 55℃, it can also be stable for a long time, which significantly benifits the transcription of RNA templates with complex secondary structure. In addition, it has a improved template affinity and cDNA synthesis efficiency. It has a good resistance to most RT-PCR inhibitors and is suitable for long-fragment cDNA amplification (as long as 20 kb).


    R201 Components


    Store at -30 ~ -15℃ and transport at ≤0℃.


    Liu, Ning, et al. "Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11. 2 translocation renal cell carcinoma." Clinical and Translational Medicine 12.4 (2022): e797.Impact Factor:11.492

    Raihan, Obayed, et al. "SRSF11 loss leads to aging-associated cognitive decline by modulating LRP8 and ApoE." Cell reports 28.1 (2019): 78-90.Impact Factor:9.423

    Huang, Yujie, et al. "A systems pharmacology approach uncovers wogonoside as an angiogenesis inhibitor of triple-negative breast cancer by targeting hedgehog signaling." Cell chemical biology 26.8 (2019): 1143-1158.Impact Factor:8.116

    Yan, Yi, et al. "Electron Transfer Flavoprotein (ETF) α Controls Blood Vessel Development by Regulating Endothelial Mitochondrial Bioenergetics and Oxygen Consumption." Oxidative medicine and cellular longevity 2022 (2022).Impact Factor:6.543

    Cat.No. :
    --- Please Select ---

    Application Notes Abstract

    Read More

    Write a review here:

  • 1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
    Loading ... Loading ...

  • nine + = 14

    Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

    Customers Also Bought: